Beclometasone vs placeboFEV1 · participants with stable stage 2 and 3 COPD (mainly FEV1 49 ± 12% predicted), ex‐smokers (majority), smokers and non‐smokers1 finding from 1 reviewBeclometasone for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyno estimate extracted1 study · 194 participantsVery low
Beclometasone/LABA vs LABALung function: FEV1 mL (change from baseline) · participants with stable stage 3 COPD, smokers and ex‐smokers with a minimum pack‐year history of 201 finding from 1 reviewBeclometasone for chronic obstructive pulmonary disease 2013 · Cochrane Headline outcomes onlyno estimate extracted1 study · 465 participantsHigh